Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2023
Date of Report: July 7, 2023
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
This filing serves as a cover document for a press release dated July 7, 2023 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material changes regarding financial performance or operations are detailed in the provided text. The document references an attached press release but does not summarize its contents.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or details on unusual items. These details are presumably contained within the referenced Exhibit 99.1 (Press Release), which is not included in the input.
Investor Verification Checklist
- Review the full text of the Press Release dated July 7, 2023 (Exhibit 99.1) for specific operational or clinical updates.
- Verify the nature of the announcement triggering this Form 6-K filing.
- Check subsequent filings for any financial impact resulting from the events described in the press release.